Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11856942 | 0.80 | SLC6A3 (0.40) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL11443179 | 0.71 | BRD4 (0.43) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL15669931 | 0.70 | MAPT (0.48) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL1895535 | 0.70 | MAPT (0.48) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL1894049 | 0.70 | MAPT (0.48) | MAPTALDH1A1GAAKDM4EKMT2A | |
| Methane SCHEMBL11336749 | 0.70 | MAPT (0.48) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL16247218 | 0.67 | MAPT (0.46) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL3966266 | 0.67 | GAA (0.47) | ALDH1A1GAACA2 | |
| SCHEMBL11837569 | 0.67 | MAPT (0.42) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL8648763 | 0.66 | ALDH1A1 (0.41) | MAPTALDH1A1GAAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | claimed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | claimed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | claimed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | claimed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | claimed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | claimed |
| US-6117840-A | INHIBITS BINDING BETWEEN VLA-4 RECEPTOR EXPRESSED ON INFLAMMATORY LEUKOCYTES AND FIBRONECTIN CS-1 PEPTIDE EXPRESSED ON ENDOTHELIAL CELLS THAT ARE INVOLVED IN IMMUNOINFLAMMATORY DISEASE STATES | CYTEL CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| US-6103870-A | INHIBITS BINDING BETWEEN VLA-4 RECEPTOR EXPRESSED ON INFLAMMATORY LEUKOCYTES AND FIBRONECTIN CS-1 PEPTIDE EXPRESSED ON ENDOTHELIAL CELLS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; TREATMENT OF ASTHMA | CYTEL CORPORATION (US) | 2000-08-15 | — | — | US | claimed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-5821231-A | TREATMENT OF IMMUNOINFLAMMATORY CONDITIONS | CYTEL CORPORATION (US) | 1998-10-13 | — | — | US | disclosed |
| US-5770573-A | CS-1 peptidomimetics, compositions and methods of using the same | CYTEL CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| US-5688913-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS | CYTEL CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0737204-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995015973-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| US-3973968-A | YELLOW | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | MAPT 201/4885ALDH1A1 2929/4885GAA 1593/4885 |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | MAPT 1677/4885ALDH1A1 425/4885GAA 2009/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | MAPT 164/4885ALDH1A1 2196/4885GAA 1331/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | MAPT 197/4885ALDH1A1 1704/4885GAA 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.